By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

BerGenBio AS 

Thormohlensgt 51, 5006

  Bergen    Norway
Phone: 47-535-01-564 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical






Company News
BerGenBio AS Receives Orphan-Drug Designation From FDA For BGB324 In The Treatment Of Acute Myeloid Leukaemia 11/19/2014 11:31:38 AM
BerGenBio AS Announces First Patient Dosed in BGB324 AML Trial 11/4/2014 7:41:49 AM
BerGenBio AS Granted A Prestigious Wellcome Trust Seeding Drug Discovery Award 9/23/2014 8:49:36 AM
BerGenBio AS Granted Platform Patent - Cellselect™ Platform Also Described In Peer-Reviewed Journal 9/8/2014 9:18:52 AM
BerGenBio AS Presents Positive Phase Ia Data On BGB324 At American Association for Cancer Research 4/9/2014 11:09:17 AM
BerGenBio AS Wraps Up $12.5 Million Funding Round 2/5/2014 5:34:39 AM
BerGenBio AS Presents Data At American Association for Cancer Research-ISLAC Conference On The Molecular Origins Of Lung Cancer 1/9/2014 10:34:31 AM
BerGenBio AS Release: Data Highlights BGB324 As A Potential Novel Treatment Option For Drug Resistant Chronic Myeloid Leukemia 12/17/2013 9:37:31 AM
BerGenBio AS Release: Study Published in Blood Highlights Axl Inhibition as a Novel Therapeutic Approach for Acute Myeloid Leukemia 10/1/2013 8:54:43 AM
BerGenBio AS Study Published in Blood Highlights Axl Inhibition as a Novel Therapeutic Approach for Acute Myeloid Leukemia 9/30/2013 9:15:12 AM
12
//-->